Stable indications.

We’ve all seen the multiple iterations of trials set out to establish a role for immunotherapy for gastric cancer. This Merck-funded analysis pools results among only the patients with documented microsatellite instability high (MSI-H) tumors across three phase 2-3 KEYNOTE trials, with such criteria being met by 4-7% of each individual study population. Median progression-free survival was roughly doubled or more for those receiving pembro-containing regimens versus chemo alone, confirming MSI-H status as a biomarker for pembro efficacy in advanced gastric cancer. In other words, this supports pembro’s years-long FDA indication. | Chao, JAMA Oncol 2021